Zions Bancorporation N.A. Purchases 39,708 Shares of Sanofi (NASDAQ:SNY)

Zions Bancorporation N.A. boosted its holdings in Sanofi (NASDAQ:SNY) by 33.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 158,208 shares of the company’s stock after acquiring an additional 39,708 shares during the quarter. Sanofi accounts for approximately 0.6% of Zions Bancorporation N.A.’s holdings, making the stock its 22nd largest position. Zions Bancorporation N.A.’s holdings in Sanofi were worth $7,676,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. POM Investment Strategies LLC purchased a new position in shares of Sanofi during the second quarter valued at approximately $25,000. Frazier Financial Advisors LLC bought a new stake in Sanofi in the 4th quarter worth approximately $28,000. Larson Financial Group LLC raised its stake in Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares during the last quarter. Register Financial Advisors LLC bought a new position in shares of Sanofi during the 1st quarter valued at $29,000. Finally, Johnson Financial Group Inc. purchased a new position in shares of Sanofi in the 4th quarter worth $31,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Down 1.2 %

Shares of Sanofi stock opened at $56.75 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market capitalization of $143.73 billion, a PE ratio of 28.52, a P/E/G ratio of 1.63 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97. The company’s fifty day simple moving average is $53.52 and its 200-day simple moving average is $50.08.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.95 earnings per share. As a group, equities analysts anticipate that Sanofi will post 4.23 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on SNY shares. Argus upped their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.